Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

OncoAlert and ecancer weekly roundup for September 20 - 26, 2020

Published: 28 Sep 2020

Views: 774

Rating:

Save

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

Dr Gil Morgan from OncoAlert gives his oncology highlights from social media for the week of September 20th - September 26th.

Dr Morgan starts the video by congratulating ESMO on their virtual meeting and highlights some of the studies presented.

Dr Morgan covers papers from Clinical Cancer Research, Cancer Medicine, The Lancet Oncology, JNCI and Nature Cancer on a breadth of cancer types as well as general patient care.

He also draws attention to new guidelines that have been released and #WorldCancerResearchDay

Dr Morgan closes by announcing the OncoAlert Colloquium - a two-day event on practice-changing oncology findings in each tumour type taught by OncoAlert faculty.

Follow Dr Morgan on twitter: @OncoAlert

Follow ecancer on twitter: @ecancer

Related Videos

Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC

Dr Shirish Gadgeel - Henry Ford Cancer Institute, Detroit, USA

Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC ( Dr Shirish Gadgeel - Henry Ford Cancer Institute, Detroit, USA )

Supporting breast cancer patients in Vietnam

Ms Thu Ha Hoang - Founder, Kien Cuong Cancer Support Club, Vietnam

Supporting breast cancer patients in Vietnam ( Ms Thu Ha Hoang - Founder, Kien Cuong Cancer Support Club, Vietnam )

TARGeted IORT INTRABEAM is a useful treatment option for early stage breast...

Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German

TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer ( Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German )

Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity...

Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain

Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity for patients with nonsquamous NSCLC ( Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain )

T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable...

Dr Ian Krop - Yale Cancer Center, Connecticut, USA

T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable and/or mBC previously treated with T-DM1 ( Dr Ian Krop - Yale Cancer Center, Connecticut, USA )

Systemic anti-cancer performance matrix

Prof Richard Sullivan, Kari Leung and Megan McLeod

Systemic anti-cancer performance matrix ( Prof Richard Sullivan, Kari Leung and Megan McLeod )

HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan

Prof Naoto Ueno - The University of Texas MD Anderson Cancer Center, Houston...

HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan ( Prof Naoto Ueno - The University of Texas MD Anderson Cancer Center, Houston, USA )

OncoAlert and ecancer weekly round up for August 8th - 14th, 2022

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly round up for August 8th - 14th, 2022 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

Lack of access to new cancer medicines in LMICs

Dr Bishal Gyawali - Queen's University, Kingston, Canada

Lack of access to new cancer medicines in LMICs ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

More from ecancer